Kortikoid (Triamcinolone Acetonide)

Triamcinolone acetonide is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors. The drug‑receptor complex alters gene transcription, increasing anti‑inflammatory proteins and decreasing pro‑inflammatory mediators like cytokines, prostaglandins and leukotrienes, which together suppress skin inflammation.

The exact dosing regimen for Kortikoid is determined by the prescribing clinician based on the severity of the condition, patient age and treatment area. Generally, a thin layer is applied to the affected skin once or twice daily, following the prescriber’s instructions.

Safety data for triamcinolone acetonide in pregnancy and lactation are limited. The product is classified as pregnancy category unknown. Healthcare providers should evaluate the potential benefits against possible risks before prescribing Kortikoid to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kortikoid (triamcinolone acetonide) is a medium‑potency corticosteroid, offering a balance between efficacy and safety. Compared with higher‑potency agents like clobetasol, it carries a lower risk of skin atrophy, while providing stronger anti‑inflammatory action than low‑potency options such as hydrocortisone.

Store Kortikoid at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Kortikoid is applied topically to clean, dry skin. Use a thin, even layer over the affected area and gently rub it in. Avoid covering the treated skin with occlusive dressings unless directed by a healthcare professional.

Serious risks include skin atrophy, telangiectasia, secondary infections, systemic adrenal suppression and, in rare cases, Cushingoid features. Patients should be monitored for these effects, especially with prolonged use, large surface areas or when combined with other corticosteroids.

Kortikoid should be avoided in individuals with known hypersensitivity to triamcinolone acetonide or any formulation component, untreated bacterial, viral or fungal skin infections, and in patients where systemic corticosteroid exposure is contraindicated without medical supervision.